Alkermes plc. (ALKS)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834

A+

Pipeline Grade

Financial Position (from SEC Filings)

$351.6M

Cash & Equivalents

$165.7M

Quarterly Burn Rate

6 mo

Est. Cash Runway

$8,657M

Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug	Phase	Indications
NALTREXONE VIVITROL	APPROVED	—

NCT #	Title	Phase	Status	Enrollment
NCT05028062	Naltrexone in AUD Reward Drinkers	PHASE4	Recruiting	60
NCT05495984	Neuroplasticity in Maternal Opioid Use Disorder (OUD)	OTHER	Recruiting	15
NCT07502443	A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2	PHASE3	Recruiting	176
NCT04987229	Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects	PHASE3	Enrolling By Invitation	236
NCT07540897	A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 ...	PHASE3	Recruiting	150
NCT07455383	A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1	PHASE3	Recruiting	150
NCT05303064	Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I...	PHASE3	Recruiting	220
NCT06767683	A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia	PHASE3	Recruiting	256
NCT06843590	A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia	PHASE2	Recruiting	126

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

Date	Type	Description	Link
2026-06-15	8-K	Alkermes plc. (ALKS) (CIK 0001520262) - EX-99.1	EDGAR

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ALKS.

All SEC filings for Alkermes plc. on EDGAR.

View all upcoming FDA catalysts across all biotech companies.